Skip to end of metadata
Go to start of metadata

Chair:  @Marti

Scribe: @Lindsey Hoggle

Call Info:

Join the online meeting: 

Join Zoom Meeting

Meeting ID: 975 3261 9039

Password: 881105

One tap mobile

+13017158592,,97532619039# US (Germantown)

+16465588656,,97532619039# US (New York)

Dial by your location

Meeting ID: 975 3261 9039

Find your local number:

NOTE: This attendance applies if you are present at the related meeting/call, regardless if you have signed a different attendance for your WG. 






     XLindsey Hoggle
     XLaura Heermann-Langford
     XMarti Velezis


     XLaura Heermann-Langford

Minutes Approved as Presented 

This is to approve minutes via general consent. "You have received the minutes. Are there any corrections to the minutes? (pause) Hearing none, if there are no objections, the minutes are approved as printed."

Agenda Topics

Agenda Outline

Agenda Item


Decision Link(if not child)
ManagementPast Minutes approval by consensus


Have document in Google docs 

will be added to Confluence.

"Structured Reports for Intravascular Access and Related Vascular DIsease" is the new name.

Plan is to show it on 07/23 for committee and/or send out today and approve for next week's call. 

Completely rewrote the short and long description for the FHIR IG final publication.

VANGUARD CDA Venous Access spreadsheet 

Documents they are working off of: VANGUARD CDA Venous Access.

Resource documents should not be edited.  Includes tabs for data dictionary (DD).

Intent is to model classes in FHIR.

As content is worked on, use red, yellow and green to designate completion.

Next CallTasks for follow up

 Adjourned at

Supporting Documents

Outline Reference

Supporting Document

Minute Approval


Introduction to VANGUARD Working Group:

Dear Colleagues,

Please join us for our first HL7 call for the VANGUARD Coordinated Registry Network. The purpose of this call will be introductory.

VANGUARD CRN is working on developing standardized vocabulary in the vascular access (especially chronic central venous access) domain, across all stakeholders. There is an approved HL7 PSS, with sponsorship from CIC and co-sponsorship from CIMI.

VANGUARD is also working with a coalition to evolve an infrastructure that will identify COVID-19 contacts and improve containment of infectious transmission

This solution relies heavily on a quantum privacy network and data access authorization. It will make use of data sourcing from CDC, state and local health authorities, and the Veterans Administration as well as other relevant data repositories containing identities of known COVID-19-infected individuals (index cases). Project partners will construct secure link relationships for these index cases, and search persistence links with potential contacts. 

The system will communicate with potential contacts with higher risk profiles. Communication includes notification of potential contact risk, education regarding contact risk, and recommendations for risk mitigation (extreme social distancing, self-quarantine, testing, etc.). 

The system will also enroll and consent potential contacts, requesting various levels of access to contact health data relevant to suspicious signs and symptoms, co-morbidities, and other factors that may increase likelihood of infection, risk of complicated infection, and risk of re-transmission.

Reporting of high-risk potential contacts to health authorities and heat map analysis will assist tracking of patterns of transmission and direct appropriate resources and response. 

Kind regards,


Kevin M. Baskin, MD

CEO, VANGUARD Medical Systems